Sinovac Biotech Ltd. Stock price

Equities

SVA

AGP8696W1045

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2019-02-22 pm EST 5-day change 1st Jan Change
6.47 USD -0.31% Intraday chart for Sinovac Biotech Ltd. -.--% -.--%
Sales 2021 19.37B Sales 2022 1.49B Capitalization 642M
Net income 2021 8.47B Net income 2022 114M EV / Sales 2021 -0.65 x
Net cash position 2021 13.27B Net cash position 2022 11.24B EV / Sales 2022 -7.1 x
P/E ratio 2021
0.09 x
P/E ratio 2022
6.49 x
Employees 3,558
Yield 2021 *
-
Yield 2022
-
Free-Float 67.49%
More Fundamentals * Assessed data
Dynamic Chart
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital cancelled the acquisition of 10.04% stake in Sinovac Biotech Ltd. CI
Scientists see risk of lost opportunity for long COVID research in China RE
Sinovac Biotech Ltd. Reports on the Clinical Trial Progress of Its Anti-Covid-19 Antibody Sa55 Injection CI
Alternative Liquidity Index LP, a fund managed by Alternative Liquidity Capital made an offer to acquire 10.04% stake in Sinovac Biotech Ltd. for an offer per share of $0.03. CI
Sinovac Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Sinovac Biotech Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
China mRNA vaccine development jumps into high gear RE
Sinovac Biotech Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
BioNTech COVID-19 Vaccines Shipped to China From Germany MT
Sinovac Biotech Says World Health Organization Approved Varicella Vaccine MT
Sinovac Varicella Vaccine Prequalified by WHO CI
Indonesia approves first home-grown COVID vaccine for emergency use - media RE
Sinovac Biotech Gets Chilean Health Regulator Approval to Start Clinical Trial for Its Omicron Containing COVID-19 Vaccine MT
Sinovac Biotech Ltd. Announces the Chilean Public Health Institute Approve Phase II Clinical Trial for Its Inactivated Omicron Strain CI
SINOVAC COVID-19 Vaccine Approves for Use in Children Above 6 months of Age in Hong Kong CI
More news
Managers TitleAgeSince
Chief Executive Officer 60 03-08-31
Director of Finance/CFO 57 -
Chief Operating Officer 47 16-03-31
Members of the board TitleAgeSince
Director/Board Member 62 04-06-30
Chief Executive Officer 60 03-08-31
Director/Board Member 55 11-05-30
More insiders
Date Price Change Volume

Delayed Quote Nasdaq, February 22, 2019 at 04:00 pm EST

More quotes
Sinovac Biotech Ltd. (Sinovac) is a holding company. The Company is a biopharmaceutical company that focuses on the research, development, manufacturing and commercialization of vaccines that protect against human infectious diseases, including hepatitis A, hepatitis B, seasonal influenza, Haemagglutinase5 Neuraminidase1 (H5N1) and Influenza A (H1N1) pandemic influenza and mumps. The Company's pipeline consists of vaccine candidates in the clinical and pre-clinical development Phases in China. The Company is engaged in the sales, marketing, manufacturing and development of vaccines for infectious disease. The Company develops various products, including Healive, Bilive, Anflu, Panflu Whole Viron Pandemic Influenza Vaccine, Split Viron Pandemic Influenza Vaccine, Panflu.1, RabEnd, Mumps Vaccine, Enterovirus 71 (EV71) Vaccine, Pneumococcal Polysaccharide Vaccine, Pneumococcal Conjugate Vaccine, Rubella Vaccine, Varicella Vaccine and Sabin Inactivated Polio Vaccine.
More about the company
  1. Stock
  2. Equities
  3. Stock Sinovac Biotech Ltd. - Nasdaq